Oral surveillance - tofacitinib vs TNFi in high risk pts: more infections, serious infection (SIEs) & non-serious infx with Tofa vs TNFi. SIE risk 17%-48% higher; SIE higher w/ high dose Tofa, esp in pts aged≥65. Usual risk factors - age, pred, comorbid. https://t.co/gjD8xqtfgp https://t.co/doMd4E9ClL

Private insurance claims data suggests that in the last 5 yrs Lyme disease has increased 19% (urban) to 60% (rural areas). Prevalence highest in June & July. Top 5 states - NJ, Maine, VT, Rhode Island, Conn. https://t.co/QHnhiWLOk3 https://t.co/7fYWQe0nBh https://t.co/GYKekF4Enf

Biosimilar availability is slow coming in US (only RTX, Inflx), but by 2030 these rheumatologic biologics should be available as biosimilars: - rituximab - infliximab - adalimumab - etanercept - golimumab - abatacept - tocilizumab - ustekinumab - denosumab https://t.co/Jjy9xrk4PA https://t.co/4Ht7HSngHQ

Supplemental Vitamin D Fails to Lower Fracture Risk NEJM has published study results showing that vitamin D3 supplementation does not significantly lower fracture risk (vs. placebo) when used in generally healthy adults. https://t.co/tY1VY3hpM2 https://t.co/22FcdnvAjL

Study of Erythrocyte MTX-polyglutamates (MTX-PG1-5) levels in Crohns patients shows that age, lower GFR and subcutaneous #MTX use all significantly increase RBC MTX-polyglutamate levels (all risk factors for MTX toxicity) https://t.co/469eMqbCBC https://t.co/8LoarfIyV4

Gout Flares Up Cardiac Risks A large case-control study showed that gout patients who experienced a cardiovascular (CV) event were more likely to have had a recent (< 120 days) gout flare compared to those without CV events. https://t.co/HVmHZ0Pi7I https://t.co/XhdLTed5mr

The Approach to Difficult to Treat Rheumatoid Arthritis Tan and Buch have reviewed the approach to D2T-RA), with a new EULAR definiation of D2T-RA to foster an approach rationale and concideration of treatment options. https://t.co/CfCvgbl3VP https://t.co/OKzyY79shU

Study of 57 #RA pts. w/ ILD treated with abatacept. Lung progression in 46% before ABA. After median 27 mos of follow-up, ILD - 72% improved or stabilized - 23% worsened - 5% died. No significant change in FVC, DLCO ILD worse assoc w/ DAS28, FVC DLCO https://t.co/7H87cAJRbG https://t.co/D60QFfevpA

New Updated GRAPPA Psoriatic Arthritis Recommendations The GRAPPA treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains." https://t.co/PkDofio1eh https://t.co/kp6UEgwonV

JAMA overview of Patient Reported Outcomes (PROs) - how generated, validated, used and limitations.https://t.co/572KxUO59s https://t.co/5c6xQfZqzu

Krill Oil Effective in Knee Osteoarthritis Krill oil supplements in knee OA was shown to be superior to placebo in reducing knee pain, stiffness and function while increasing the omega-3 index. https://t.co/JkLrz5C0Pk https://t.co/XzZWXJ8zgA

Plasmacytoid Dendritic Cell Inhibitor in Cutaneous Lupus Litifilimab, a humanized monoclonal antibody against BDCA2, targets the BDCA2 receptor on plasmacytoid dendritic cells. https://t.co/qOu2jMa6EK https://t.co/LMaY7gpt05